Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients. [electronic resource]
Producer: 20190114ISSN:- 2150-7511
- Adult
- Bacteria -- classification
- Clinical Trials, Phase II as Topic
- Crohn Disease -- drug therapy
- DNA, Bacterial -- chemistry
- DNA, Ribosomal -- chemistry
- Feces -- microbiology
- Female
- Gastrointestinal Microbiome
- Humans
- Immunologic Factors -- administration & dosage
- Male
- Microbiota
- Middle Aged
- RNA, Ribosomal, 16S -- genetics
- Sequence Analysis, DNA
- Treatment Outcome
- Ustekinumab -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.